Navigation Links
3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012
Date:5/1/2013

SHENYANG, China, May 1, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has filed the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2012 with the U.S. Security and Exchange Commission on April 30, 2013. The annual report on Form 20-F, which contains its audited financial statements, can be accessed on the SEC's website at http://www.sec.gov or on the Investor section of the Company's website www.3sbio.com. Shareholders may also receive a hard copy of the annual report free of charge upon request.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

Investor Contacts

Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com  

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com


'/>"/>
SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
2. 3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
3. 3SBio Inc. Announces Unaudited First Quarter 2012 Results
4. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
5. 3SBio Inc. to Present at the UBS Greater China Conference 2012
6. Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
7. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
8. TNI BioTech Files Form 10 with SEC
9. Marrone Bio Innovations Files Patent for a Unique Bacillus Species
10. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
11. NDIS Approval of the Promega PowerPlex(R) Y23 System Enables More Usable Profiles in Less Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... United Kingdom (PRWEB) , ... February 20, 2017 ... ... and manufactures industrial metal detection solutions for the food and pharmaceutical processing and ... This award goes to the manufacturer that has done the most or taken ...
(Date:2/20/2017)... , Feb. 20, 2017  Former NFL players who had ... functions later in life, according to a preliminary study released ... Neurology,s 69th Annual Meeting in Boston , ... are complex movements where the muscles and nerves work together, ... ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) ... Orlando, Fla. , The combined scientific sessions offer investigators, clinicians, laboratory ...
(Date:2/17/2017)...  If only one in every hundred cells ... to chemotherapy, thousands of cancer cells would remain ... finding these mutations in ever-smaller subpopulations of tumor ... in blood — to guide treatment decisions and ... however, detecting these genetic anomalies may be more ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 /PRNewswire/ ... point. Driven largely by the confluence of organizations, ... users, distaste for knowledge-based systems (password and challenge ... consumer, industrial, and government systems. The market is ... been a demarcation between consumer and enterprise uses ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):